Investing
The raise brings the healthcare-focused firm's total committed capital to more than $1 billion.
The company will use the funds to expand its value-based cancer care network and extend its reach with health plans, employers and providers.
The company will use the funds to bring its AI-enabled offerings into clinical development and advance its platform and portfolio.
The life sciences company's Gut Intelligence Test will be available in 200 CVS locations and through the drugstore chain online.
Also, a new predictive algorithm can predict the survival of a patient on ECMO.
Also, HD has obtained fresh funding to expand its reach across Vietnam.
The company announced its expansion into a Silicon Valley-based production facility to develop its collaborative robotic system.
The company's revenue increased in Q2 of this year to $13.1 million compared to $10.7 million in the first quarter – still below the $18.3 million reported in Q2 2022.
The company will use the funds to grow its offerings, including its teletherapy platform, and expand its reach nationally.
Shawn Ellis, managing partner at Distributed Ventures, tells MobiHealthNews why and how the firm's recent raise will go toward advancing digital health.